Reply to Auclin et al. Comment on "Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176".
Ashley M HopkinsGanessan KichenadasseAhmad Y AbuhelwaRoss A McKinnonAndrew RowlandMichael J SorichPublished in: Cancers (2021)
We thank Auclin et al. [...].